InsiderTrades.com logo
Jim Cramer’s “The Biggest Drug Ever”
From Behind the Markets   |   Ad
This firm's breakthrough has drawn investments from the biggest names in Big Pharma - With companies like Biogen, Sanofi, and Genentech pouring over $1 billion into it.
Unlock the details of this groundbreaking opportunity here...
Francois Lebel net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Francois Lebel Biography and Net Worth

Insider of Spectrum Pharmaceuticals
Francois Lebel has served as our Executive Vice President and Chief Medical Officer since November 2018. Prior to joining Spectrum, he provided strategic leadership on eight NDA/BLAs in various therapeutic areas and on several mergers and acquisitions. Dr. Lebel has broad and deep experience in oncology drug development, medical affairs, regulatory and pharmacovigilance acquired through various roles of increasing responsibilities at Chiron (Novartis), Warner-Lambert (Pfizer) and Burroughs Wellcome (GSK). From March 2013 to October 2018, Dr. Lebel served as Executive Vice President, Research and Development, and Chief Medical Officer at ZIOPHARM Oncology. He also held various leadership roles including Vice President of Research and Development at Baxter International and Global Head of Medical and Scientific Affairs at MedImmune.

Dr. Lebel brings nearly 30 years of clinical leadership experience within the biopharmaceutical industry. He has designed and managed global medical organizations to deliver results, enhance productivity and practice sound risk management.

Dr. Lebel completed his residency in Internal Medicine (Infectious Disease) and Medical Microbiology at McGill University and his research fellowship in infectious disease at Harvard Medical School.

Dr. Lebel holds a bachelor’s degree in molecular biology from University of Ottawa, Canada and a medical degree from University of Ottawa, Canada.

What is Francois Lebel's net worth?

The estimated net worth of Francois Lebel is at least $671,000.71 as of June 22nd, 2022. Dr. Lebel owns 651,457 shares of Spectrum Pharmaceuticals stock worth more than $671,001 as of April 25th. This net worth approximation does not reflect any other investments that Dr. Lebel may own. Learn More about Francois Lebel's net worth.

How do I contact Francois Lebel?

The corporate mailing address for Dr. Lebel and other Spectrum Pharmaceuticals executives is 11500 SOUTH EASTERN AVENUE SUITE 240, HENDERSON NV, 89052. Spectrum Pharmaceuticals can also be reached via phone at (617) 586-3900 and via email at [email protected]. Learn More on Francois Lebel's contact information.

Has Francois Lebel been buying or selling shares of Spectrum Pharmaceuticals?

Francois Lebel has not been actively trading shares of Spectrum Pharmaceuticals during the last ninety days. Most recently, Francois Lebel sold 6,096 shares of the business's stock in a transaction on Wednesday, June 22nd. The shares were sold at an average price of $0.81, for a transaction totalling $4,937.76. Following the completion of the sale, the insider now directly owns 651,457 shares of the company's stock, valued at $527,680.17. Learn More on Francois Lebel's trading history.

Who are Spectrum Pharmaceuticals' active insiders?

Spectrum Pharmaceuticals' insider roster includes Seth Fischer (Director), Francois Lebel (Insider), Keith Mcgahan (Insider), and Thomas Riga (COO). Learn More on Spectrum Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Spectrum Pharmaceuticals?

During the last twelve months, insiders at the biotechnology company sold shares 1 times. They sold a total of 32,387 shares worth more than $35,625.70. The most recent insider tranaction occured on May, 26th when CFO Nora Brennan sold 32,387 shares worth more than $35,625.70. Insiders at Spectrum Pharmaceuticals own 2.7% of the company. Learn More about insider trades at Spectrum Pharmaceuticals.

Information on this page was last updated on 5/26/2023.

Francois Lebel Insider Trading History at Spectrum Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/22/2022Sell6,096$0.81$4,937.76651,457View SEC Filing Icon  
4/4/2022Sell1,205$1.35$1,626.75252,513View SEC Filing Icon  
2/23/2022Sell13,466$0.70$9,426.20View SEC Filing Icon  
11/8/2021Sell7,363$2.20$16,198.60View SEC Filing Icon  
6/23/2021Sell5,000$4.00$20,000.00345,046View SEC Filing Icon  
4/5/2021Sell1,125$3.31$3,723.75351,892View SEC Filing Icon  
11/9/2020Sell5,000$3.56$17,800.00301,424View SEC Filing Icon  
11/6/2020Sell7,025$3.50$24,587.50301,424View SEC Filing Icon  
6/22/2020Sell5,474$3.16$17,297.84296,896View SEC Filing Icon  
4/2/2020Sell1,228$2.17$2,664.76303,224View SEC Filing Icon  
11/6/2019Sell6,963$8.16$56,818.08113,970View SEC Filing Icon  
See Full Table

Francois Lebel Buying and Selling Activity at Spectrum Pharmaceuticals

This chart shows Francois Lebel's buying and selling at Spectrum Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Spectrum Pharmaceuticals Company Overview

Spectrum Pharmaceuticals logo
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. It offers ROLVEDON(Eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia. The company develops Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and license agreement with Therapyx, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $1.03
Low: $1.03
High: $1.03

50 Day Range

MA: $1.01
Low: $0.94
High: $1.03

2 Week Range

Now: $1.03
Low: $0.32
High: $1.57

Volume

N/A

Average Volume

1,927,028 shs

Market Capitalization

$211.41 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.15
Jim Cramer’s “The Biggest Drug Ever”
From Behind the Markets   |   Ad
This firm's breakthrough has drawn investments from the biggest names in Big Pharma - With companies like Biogen, Sanofi, and Genentech pouring over $1 billion into it.
Unlock the details of this groundbreaking opportunity here...